Union Minister for Health and Family Welfare Shri Jagat Prakash Nadda Virtually Addresses Press Briefing at World Health Organization Headquarters; Reaffirms India’s Commitment to Eliminating Cervical Cancer and Advancin...

1. At a Glance

• Union Health Minister J.P. Nadda virtually addressed a press briefing at WHO Headquarters, Geneva, reaffirming India's endorsement of the WHO 90-70-90 cervical cancer elimination targets for 2030. [S1][S2]
• India's multi-pronged strategy combines prevention (HPV vaccination), screening (VIA), early detection, and treatment under the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD). [S1]
• Relevant for UPSC: Global health diplomacy, Sustainable Development Goal 3, public-health flagship schemes (Ayushman Arogya Mandirs, U-WIN), India-WHO cooperation. [S1][S3]

2. Why in the News

• March 2026: JP Nadda virtually addressed press briefing at WHO HQ on cervical cancer elimination. [S1]
• 28 February 2026: PM Narendra Modi launched the nationwide HPV vaccination drive from Ajmer, Rajasthan, targeting ~1.15 crore (≈12 million) adolescent girls — termed by DG WHO Dr. Tedros Adhanom Ghebreyesus as the "world's largest free vaccination drive" against cervical cancer. [S1][S3][S4]

3. Background & Evolution

• 2020: WHO launched Global Strategy to Accelerate Elimination of Cervical Cancer — first cancer ever targeted for elimination by WHO. [S2]
• 2022: India's indigenously developed quadrivalent vaccine CERVAVAC announced (Serum Institute of India + DBT-BIRAC). [S4]
• 2023-24: Interim Budget (Finance Minister Nirmala Sitharaman) flagged HPV vaccination for girls aged 9–14. [S4]
• NP-NCD rolled out under National Health Mission with population-based screening for common NCDs including oral, breast and cervical cancer. [S1]
• Feb 2026: Nationwide HPV vaccination campaign formally launched. [S3]

4. Core Static Facts

• Implementing ministry: Ministry of Health and Family Welfare (MoHFW). [S1]
• Scheme vehicle: NP-NCD under National Health Mission; delivery at Ayushman Arogya Mandirs (rebranded HWCs). [S1]
• Screening method offered: VIA (Visual Inspection with Acetic Acid) for women aged 30–65 years. [S1]
• Women screened for cervical cancer (cumulative): >86 million under NP-NCD. [S1]
• HPV vaccine target cohort: adolescent girls (campaign focus on 14-year-olds; WHO recommends 9–14). [S3][S4]
• WHO 90-70-90 targets (by 2030): 90% of girls fully vaccinated with HPV vaccine by age 15; 70% of women screened with a high-performance test by 35 and 45; 90% of women with pre-cancer/cancer receive treatment. [S2]
• Digital backbone: U-WIN portal tracks HPV vaccination status. [S4]
• Vaccines in use: Gardasil (quadrivalent) and indigenous CERVAVAC (Serum Institute of India). [S4]

5. Multi-Dimensional Analysis

Social / Gender - Cervical cancer is the 2nd most common cancer among Indian women; elimination directly advances gender equity in health outcomes. [S4] - Free vaccination removes affordability barrier for adolescent girls, especially rural cohorts via Ayushman Arogya Mandirs. [S1]

Scientific / Technological - Indigenous CERVAVAC showcases Atmanirbhar Bharat in biologics (DBT-BIRAC + SII partnership). [S4] - U-WIN integrates HPV doses into India's digital immunisation stack (extension of Co-WIN architecture). [S4]

Geopolitical / Global Health Diplomacy - India's pitch at WHO HQ frames it as a leader in Global South health cooperation; aligns with Quad Cancer Moonshot Initiative. [S1] - DG WHO's endorsement strengthens India's soft power in multilateral health forums. [S1]

Administrative - Cooperative federalism — states deliver via schools/health facilities; Centre supplies vaccine through Universal Immunisation Programme architecture. [S3] - Cold-chain and tracking through U-WIN reduces dropout risk. [S4]

Economic - A Lancet-cited modelling: achieving 90-70-90 could save >10.6 million lives by 2120 in India — large averted-DALY gains. [S2]

6. Recent Developments (last 12-18 months)

• 28 Feb 2026: PM Modi launches nationwide HPV vaccination drive at Ajmer, Rajasthan. [S3]
• March 2026: JP Nadda's virtual press briefing at WHO HQ Geneva. [S1]
• 2025: 2nd AIIMS Oncology Conclave at NCI-AIIMS Jhajjar inaugurated by Nadda; >26 crore screened for oral cancer under NP-NCD reported. [S5]
• Expansion of Ayushman Arogya Mandirs as the screening delivery point for VIA. [S1]

7. Prelims Hooks

• NP-NCD = National Programme for Prevention and Control of Non-Communicable Diseases (under NHM, MoHFW). [S1]
• Screening for cervical cancer uses VIA (Visual Inspection with Acetic Acid), not Pap smear, at primary level. [S1]
• Target age group for VIA screening at Ayushman Arogya Mandirs: 30–65 years. [S1]
• Ayushman Arogya Mandirs = rebranded Health & Wellness Centres under Ayushman Bharat. [S1]
• Cumulative cervical-cancer screenings under NP-NCD: >86 million women. [S1]
• CERVAVAC = India's first indigenous quadrivalent HPV vaccine (Serum Institute + DBT-BIRAC, 2022). [S4]
• WHO's elimination targets: 90-70-90 by 2030. [S2]
• HPV vaccination launched nationwide on 28 February 2026 from Ajmer. [S3]
• Digital tracking platform: U-WIN. [S4]
• DG WHO: Dr. Tedros Adhanom Ghebreyesus. [S1]
• WHO age recommendation for HPV vaccination: girls aged 9–14. [S2]
• Cervical cancer is the only cancer with a WHO global elimination strategy (2020). [S2]
• Threshold for "elimination as public health problem": <4 cases per 100,000 women. [S2]

8. Mains Relevance

• GS-II: Government policies and interventions for health; India's role in international health institutions (WHO).
• GS-III: Science & Technology — indigenous vaccine development; Public Health.
• Plausible question stems: 1. "Discuss India's strategy to achieve WHO's 90-70-90 cervical cancer elimination targets by 2030. What are the implementation bottlenecks?" 2. "Examine the significance of indigenous vaccines like CERVAVAC for India's health security and South-South cooperation." 3. "Population-based NCD screening at Ayushman Arogya Mandirs marks a paradigm shift from curative to preventive health. Critically evaluate."

9. Related Topics to Study Next

• Ayushman Bharat — PMJAY & Health and Wellness Centres / Ayushman Arogya Mandirs — delivery platform for screening.
• Universal Immunisation Programme (UIP) and Mission Indradhanush — into which HPV vaccine is being integrated.
• National Health Mission (NHM) — funding and federal architecture for NP-NCD.
• WHO Global Strategy on NCDs (2013–2030) and SDG-3.4 — global frame.
• Quad Cancer Moonshot Initiative (2024) — geopolitical health cooperation.
• CoWIN / U-WIN digital health stack — administrative tech base.
• PM-ABHIM (Ayushman Bharat Health Infrastructure Mission) — post-COVID public-health capacity.
• National Cancer Grid & NCI-AIIMS Jhajjar — tertiary cancer-care ecosystem.

10. Common Errors / Trap Areas

• NP-NCD ≠ National Health Mission; NP-NCD is a programme within NHM. [S1]
• VIA (not Pap smear or HPV-DNA test) is the primary screening modality at Indian sub-district level. [S1]
• CERVAVAC is quadrivalent (not bivalent or nonavalent); developed by Serum Institute of India, not Bharat Biotech. [S4]
• The WHO target sequence is 90-70-90 (vaccinate-screen-treat), not 90-90-90 (HIV target).
• Age band confusion: WHO recommends HPV vaccination at 9–14; VIA screening covers 30–65. [S1][S2]
• Ayushman Arogya Mandir is the new name of HWC — not a separate scheme.

11. Sources

• [S1] Union Minister Shri JP Nadda Virtually Addresses Press Briefing at WHO HQ — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2235710 — (tier: 1)
• [S2] Elimination Planning Tool: Advancing Towards Cervical Cancer Elimination India (IARC/WHO) — https://gco.iarc.who.int/media/elimination_tool/factsheets/356-IND-india.pdf — (tier: 2)
• [S3] PM Modi Launches Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer, Rajasthan — https://www.pib.gov.in/PressReleseDetailm.aspx?PRID=2233906 — (tier: 1)
• [S4] Cervical Cancer Vaccination Campaign Launched — Key Takeaways (PIB) — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc2026228807201.pdf — (tier: 1)
• [S5] JP Nadda inaugurates 2nd AIIMS Oncology Conclave 2025 at NCI-AIIMS Jhajjar — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2103588 — (tier: 1)